Jun 9, 2022
A Strategic Relocation to Baltimore Supports one Biomedical Company’s Growth June. 9th, 2022 KaloCyte’s Co-founders made the best of both worlds right in the heart of Baltimore: The St. Louis-founded startup moved into CBOTH as a University of Maryland BioPark...
May 1, 2022
One of KaloCyte’s co-founders, Dr. Allan Doctor, was among several experts interviewed for and quoted in the article on synthetic blood research, and KaloCyte’s ErythroMer and developmental status is featured. Click here to read the article featured in The Washington...
Nov 8, 2021
BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling KaloCyte to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and...
Dec 4, 2020
The University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state, including KaloCyte, with the $10 million Maryland Momentum Fund (MMF). Click here to read the article featured in Catalyst magazine, a UMB publication.
Jul 21, 2020
Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer. Click here to read the news release issued by Old Line Capital.
Jun 8, 2020
Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions. Click here to read the article in its entirety. Stephen Babcock, assistant editor for Technical.ly, highlights the company’s recent round of investment...
